STUDY PROTOCOL

TRUE-1: Trial of Repurposed Unithiol for snakebite
Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults) [version 1; peer review: awaiting peer review]

Michael Abouyannis1,2, Richard FitzGerald3, Mwanajuma Ngama2, Hope Mwangudzah2, Yvonne K. Nyambura2, Samson Ngome2, Debra Riako2, Lawrence Babu2, Frida Lewa2, Laura Else4, Sujan Dily Penchala4, Benedict Orindi2, Noni Mumba2, Betty Kalama2, Francis M. Ndungu2, Ifedayo Adetifa2,5, Saye Khoo3,4, David G. Lalloo1, Nicholas R. Casewell1,6, Mainga Hamaluba2,7

1Centre for Snakebite Research & Interventions, Liverpool School of Tropical Medicine, Liverpool, UK
2KEMRI-Wellcome Research Programme, Kilifi, Kenya
3NIHR Royal Liverpool and Broadgreen CRF, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
4Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
5Department of Infectious Diseases Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
6Centre for Drugs & Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK
7Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Abstract

Background: Snakebites affect over 5 million people each year, and over 100,000 per year die as a result. The only available treatment is antivenom, which has many shortcomings including high cost, intravenous administration, and high risk of adverse events. One of the most abundant and harmful components of viper venoms are the zinc-dependent snake venom metalloproteinases (SVMPs). Unithiol is a chelating agent which is routinely used to treat heavy metal poisoning. In vivo experiments in small animal models have demonstrated that unithiol can prevent local tissue damage and death caused by a certain viper species. This phase I clinical trial will assess the safety of ascending doses of unithiol with a view for repurposing for snakebite indication.

Methods: This open label, single agent, phase I clinical trial of a repurposed drug has a primary objective to evaluate the safety of escalating doses of unithiol, and a secondary objective to describe its pharmacokinetics. In total, 64 healthy Kenyan volunteers from Kilifi County will be dosed in consecutive groups of eight, with dose escalation decisions dependent on review of safety data by an
independent data safety monitoring board. Four groups will receive ascending single oral doses, two will receive multiple oral doses, and two will receive single intravenous doses. Follow-up will be for 6-months and includes full adverse event reporting. Pharmacokinetic analysis will define the Cmax, Tmax, half-life and renal elimination. **Conclusions:** This clinical trial will assess the safety and tolerability of a promising oral therapeutic in a relevant setting where snakebites are prevalent. Unithiol is likely to be safer than antivenom, is easier to manufacture, has activity against diverse snake species, and can be administered orally, and thus shows promise for repurposing for tropical snakebite. **Pan African Clinical Trials Registry:** PACTR202103718625048 (3/3/2021) **Keywords** Snakebite, envenoming, small molecule, chelator, phase I, adaptive, repurpose, clinical trial.
When good quality antivenom directed against the relevant biting species is available, it has been shown to effectively reverse the consumption coagulopathy induced by SVMPs. However, few clinical trials of antivenom in sub-Saharan Africa have been conducted, and none have compared antivenom to placebo\textsuperscript{6-10}. In Nigeria, “EchiTAb Plus-ICP” (ET-Plus) equine antivenom restored the 20-minute whole-blood clotting time (20WBCT) in 83% of trial participants\textsuperscript{8}. Despite access to effective antivenom, in Nigeria snakebites are estimated to contribute to 1,900 deaths and 2,400 amputations, annually\textsuperscript{11}. Unfortunately, antivenom has limited efficacy for treating venom-induced local tissue damage, probably because the onset of local tissue damage occurs before most people can access treatment\textsuperscript{12,13}. The costs, low availability, risk of anaphylaxis and cold chain requirements of antivenom have restricted its use to secondary care settings. The risk of allergic reaction varies significantly between antivenom products. In a clinical trial conducted in Sri Lanka, the adverse reaction rate was 75%, and 43% suffered a severe adverse reaction\textsuperscript{14}.

**SVMP inhibitory action of metal chelators**

In the 1950s, in vitro experiments found that incubating venom with ethylenediaminetetraacetic acid (EDTA) completely inactivated its proteolytic activity\textsuperscript{15,16}. Rabbits injected with venom that had been pre-incubated with EDTA were found to develop less necrosis\textsuperscript{17}. In 1978, the importance of zinc in the haemorrhagic and proteolytic activities of venom components was described, and it was found that removing zinc with a metal chelator (1,10-phenanthroline) inhibited these activities\textsuperscript{18}. More recently, research in mice has shown that administering CaNa\textsubscript{2}EDTA inhibits haemorrhagic, proteolytic and dermonecrotic effects of *Bothrops asper* venom\textsuperscript{19}. In mice administered with a 2.5x LD\textsubscript{50} dose of *Echis ocellatus* venom pre-incubated with EDTA, lethality was abolished. Furthermore, EDTA outperformed heterologous antivenom in terms of mice survival and survival times\textsuperscript{20}. *In vitro* and mouse model research has since investigated the efficacy of various metal chelators to inhibit the pathological activity of various saw-scaled viper (*Echis* spp.) venoms\textsuperscript{21}. Of those tested, unithiol (also known as sodium D,L-2,3-dimercaptopropanesulfonic acid [DMPS], trade name Dimaval\textsuperscript{8}) showed the most promise as it is already in routine clinical use, has activity against a range of snake species, and significantly reduces envenomating associated mortality *in vivo*\textsuperscript{22}. As well as preventing mortality, unithiol was demonstrated to effectively inhibit the formation of local haemorrhagic lesion at the site of venom delivery\textsuperscript{21}. When unithiol was co-administered with antivenom *in vivo*, there was an additive effect with the combination treatment reducing mortality more than either product alone\textsuperscript{21}.

**Summary of existing safety data for unithiol**

Safety data in humans is available for unithiol, as this drug is routinely used for the treatment of heavy metal poisoning. Unithiol is generally regarded as a safe and well tolerated therapy.

**Skin reactions**

Skin reactions are the most common side effect reported for unithiol. They are invariably of low severity and of minor and short

---

Abbreviations

- 20WBCT: 20-minute whole-blood clotting time
- ALT: Alanine aminotransferase
- AUC: Area under the curve
- CGMRC-C: Centre for Geographic Medicine Coast
- Cmax: Maximum plasma concentration
- CRF: Case Report Form
- CSRI: The Centre for Snakebite Research & Interventions
- DMPS: 2,3-bis(sulfanyl)propane-1-sulfonic acid (unithiol)
- EDTA: Ethylenediaminetetraacetic acid
- FBC: Full blood count
- GDPR: General data protection regulation
- KEMRI: Kenya Medical Research Institute
- KHDSS: The Kilifi Health and Demographic Surveillance System
- LSTM: Liverpool School of Tropical Medicine
- SERU: Scientific and Ethics Review Unit
- SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials
- SVMP: Snake venom metalloproteinase toxins
- Tmax: Time to maximum concentration
- CGMRC-C: Centre for Geographic Medicine Coast
- Cmax: Maximum plasma concentration
- CRF: Case Report Form
- CSRI: The Centre for Snakebite Research & Interventions
- DMPS: 2,3-bis(sulfanyl)propane-1-sulfonic acid (unithiol)
- EDTA: Ethylenediaminetetraacetic acid
- FBC: Full blood count
- GCP: Good clinical practice
- GDPR: General data protection regulation
- KEMRI: Kenya Medical Research Institute
- KHDSS: The Kilifi Health and Demographic Surveillance System
- LSTM: Liverpool School of Tropical Medicine
- SERU: Scientific and Ethics Review Unit
- SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials
- SVMP: Snake venom metalloproteinase toxins
- Tmax: Time to maximum concentration

**Introduction**

The burden of snakebite envenoming

Globally, snakebite envenoming is estimated to affect 1.8–2.7 million people, with annual mortality predicted between 80,000 and 140,000\textsuperscript{4-6}. Despite this high mortality rate, snakebite envenoming has attracted minimal research funding, and therapeutic options have changed little over the past 50 years\textsuperscript{3-4}.

**Snake venom metalloproteinase toxins**

Snake venom metalloproteinase toxins (SVMPs) are abundant in viperid snake venoms and have an important role in causing:

- Haemorrhage via hydrolysis of endothelial cell wall components including type IV collagen, hyaluronic acid, and proteoglycans.
- Consumption coagulopathy via the activation of blood clotting factors.
- Local tissue damage, which is a prominent feature of envenoming in sub-Saharan Africa.

**Limitations of antivenom**

The mainstay of snakebite treatment is antivenom, which consists of polyclonal antibodies purified from immunised mammals, such as horses. Antivenom efficacy is variable and high costs have impacted on availability, particularly in sub-Saharan Africa\textsuperscript{3}.
impact to the individual. The rash is reversible on stopping the medication. These reactions are usually allergic in nature and tend to increase in likelihood with subsequent doses of unithiol.

Very rarely, unithiol can cause Stevens-Johnson syndrome. There are two published cases of Stevens-Johnson syndrome occurring during treatment with unithiol\textsuperscript{22,23}. Given that unithiol has been in clinical use for several decades and has been given to many thousands of people, the risk of this complication is regarded as extremely low. The report by Chisolm et al.\textsuperscript{22} does not provide any clinical details. In the report by Van Der Linde et al., a widespread rash associated with blistering of the oral mucosa occurred in an 11-year old boy treated for mercury poisoning, with oral unithiol\textsuperscript{23}. No cutaneous epidermal detachment occurred, and the child made a complete recovery following cessation of unithiol. In these case reports, the skin reaction did not manifest until 8–14 days after commencing unithiol at a dose of 200 mg three times per day oral.

Skin reactions associated with parenteral use of unithiol have only been described at very high doses. Attempts at administering parenteral 100 mg/kg to humans were conducted in the Soviet Union in the 1960s\textsuperscript{31}. The study by Sanotskiî (available in Russian only), is referred to by Aposhian’s review\textsuperscript{24}, which describes necrosis and ulceration at the site of subcutaneous or intravenous injection following these doses, which are 20 times higher than the currently recommended intravenous dose. These adverse skin reactions are not described for lower doses of parenteral unithiol.

Allergic and other immune mediated reactions
Severe allergic reactions to unithiol are extremely rare. Two cases of anaphylaxis and 21 cases of ‘hypersensitivity’ are reported in the Periodic Safety Update Report. The Dimaval\textsuperscript{25} solution for injection summary of product characteristics suggests caution in administering the drug to people with allergic asthma, due to a risk of provoking an exacerbation\textsuperscript{26}. The Periodic Safety Update Report identifies 6 reports of ‘asthma’ in association with use of unithiol.

Cardiovascular effects
Rapid infusion of unithiol solution via the intravenous route has been associated with transient asymptomatic hypotension in a single published article. In a previous pharmacokinetic study of unithiol, two of five participants developed transient falls in systolic blood pressure, of 20 mmHg\textsuperscript{27}. These episodes were not associated with any symptoms, any change in heart rate, or any fall in diastolic blood pressure. Unithiol is not cardiotoxic and is not associated with any cases of clinically significant cardiac arrhythmia.

Mineral deficiency
Although the mechanism of action of unithiol would suggest that mineral deficiency would be an expected side effect (such as magnesium or zinc deficiency), this is not borne-out in published or post-marketing data. Data from Periodic Safety Update Reports have identified only a single case defined as ‘non-serious decreased electrolytes.’ No published reports of clinically significant mineral deficiency were identified.

Renal effects
Unithiol is not nephrotoxic.

Liver effects
Unithiol is not hepatotoxic.

Effects of higher doses of unithiol
Animal toxicity data have suggested that high doses of unithiol can be tolerated. In rats, 150 mg/kg administered orally 5 times per week for 63-weeks was tolerated with no observable effects\textsuperscript{28}. In beagles, 45 mg/kg administered orally for 6-months was tolerated with no observable effects\textsuperscript{29}. When a dose of 75 mg/kg was administered intravenously twice daily to beagles, anaemia as well as reduced iron content in the liver and spleen was noted\textsuperscript{30}. In rabbits receiving 500 mg/kg administered orally twice daily for 6–10 days, no clinical events or changes in blood parameters were noted\textsuperscript{30}.

Published reports have also described giving high doses of unithiol to humans. Very high doses of parenteral unithiol (100 mg/kg) were given to people in the report by Sanotskiî in the 1960s (available in Russian only)\textsuperscript{31}. This study is referred to in Aposhian’s review\textsuperscript{24}, which describes necrosis and ulceration at the site of subcutaneous or intravenous injection. No other adverse events were described, although it is unclear if formal follow-up and adverse event reporting were followed.

The Dimaval\textsuperscript{25} product monograph includes a report of the accidental administration of 100 mg/kg parenterally\textsuperscript{32}. Skin necrosis at the injection site occurred, but no other morbidity was highlighted\textsuperscript{32}. In a study by Stantschew et al.\textsuperscript{26} in 1974 (article in German), 216 adult workers with chronic mercury exposure were administered unithiol 1,000 mg intramuscularly. No adverse events were reported\textsuperscript{26}.

In a case report by Heinrich-Ramm et al., a 21-year male with arsenic over-dose was administered the following regimen of unithiol:
- 250 mg/hour intravenously for 1 day
- 125 mg/hour intravenously on day 2
- 62.5 mg/hour intravenously on days 3–5

The total dose of unithiol received was 15.2 grams. A mild increase in transaminases were reported, but the patient was otherwise well and made a good recovery from the arsenic poisoning\textsuperscript{32}. It is uncertain whether the transaminase rise was due to arsenic poisoning or unithiol.
Summary of existing pharmacokinetic data for unithiol
In total, four studies on unithiol pharmacokinetics have been conducted by a research group at The University of Arizona. Key finding from these studies are summarised in Table 1.

Absorption
In volunteers given 3x 100 mg capsules of unithiol, the drug was detected in blood between 0.5 and 4 hours after ingestion. Maximum concentrations were seen at 4 hours.

In 4 male volunteers, oral bioavailability was 39% (range 19–62%)².

Metabolism
Unithiol is rapidly and extensively metabolised to disulphide forms, which are not thought to be effective chelators. The predominant urine metabolites of unithiol are as follows: cyclic polymeric unithiol disulphides (97%), unithiol-cysteine mixed disulphide (2.5%) and acyclic unithiol disulphide (0.5%). In volunteers receiving intravenous unithiol, only 12% of unaltered drug was detected in blood after 15 minutes.

Distribution
Disulphide metabolites of unithiol are confined to the plasma, suggesting they are plasma protein bound. In a study of three healthy adults who received a single oral dose of unithiol, at 5-hours 62.5% of the total plasma unithiol was protein bound. Most (84%) of the protein bound unithiol was in the form of unithiol-albumin complex, and this is thought to be via disulphide linkage. The remaining non-protein bound drug consisted of unithiol disulphides (36.6%) and unaltered unithiol (0.9%). Amongst five healthy volunteers given intravenous unithiol, the volume of distribution varied from 2.7 to 15.4 L/kg.

Elimination
Unithiol is subject to renal elimination. In volunteers given intravenous unithiol (3 mg/kg), the elimination half-life was 1.8 hours. Of the total unithiol dose, 10% is found in the urine in an un-altered form, whereas 74% is excreted as sulphide metabolites.

Justification for this clinical trial
There is an urgent need to develop improved therapeutics for the treatment of snakebite. Every year, over 100,000 people die from snake envenoming, and the burden is particularly high in sub-Saharan Africa and Asia. The World Health Organization has targeted a 50% reduction in morbidity and mortality by 2030, and this trial could be a key step toward achieving this ambitious goal. Unithiol shows promise as a venom inhibitor based on robust pre-clinical measures of efficacy. The advantages of unithiol over antivenom are that it is safe, orally available, demonstrates cross-species specificity and is cheaper to produce.

Although unithiol has been safely administered to people for many decades, this will be the first study to explore its use as a therapeutic for snakebite. Unlike in heavy metal poisoning, the aim will be to rapidly achieve higher plasma levels, yet it will be possible to stop treatment after only 2 or 3 days. Limited pharmacokinetic data exists for unithiol, and this will be the first trial to investigate the pharmacokinetic effects of multiple doses. This will also be the first trial to evaluate high oral doses, as all previous ‘high dose’ studies have relied on parenteral administration. Oral administration will be important for using this drug in rural tropical settings. As snakebite tends to occur in rural settings, most victims initially present to a rural clinic where an early oral dose of unithiol could be given prior to transfer. Intravenous administration will be important for

<table>
<thead>
<tr>
<th>Table 1. Summary of published human pharmacokinetic data.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paper</strong></td>
</tr>
<tr>
<td>Maiorino 1991¹³</td>
</tr>
<tr>
<td>Hurlbut 1994¹²</td>
</tr>
<tr>
<td>Maiorino 1996¹⁴</td>
</tr>
<tr>
<td>Maiorino 1996¹⁵</td>
</tr>
</tbody>
</table>

AUC, area under the curve; Cmax, maximum plasma concentration; Tmax, time to maximum concentration.
those cases that present directly to a hospital facility with the capabilities of giving intravenous medications. Considering the dose-responsiveness of unithiol in vitro, as well as the need to rapidly achieve therapeutic levels, intravenous administration may be more efficacious.

**Protocol**

**Approvals and trial registration**

This trial was registered on the Pan African Clinical Trials Registry on the 3rd of March 2021 (PACTR202103718625048).

This manuscript corresponds to the approved version 2 protocol of the TRUE-1 trial, dated 5th of November 2020. This was approved by the Kenya Medical Research Institute Scientific and Ethics Review Unit on the 13th of January 2021 and by the Liverpool School of Tropical Medicine Research Ethics Committee on the 18th of February 2021. Regulatory approval for this protocol was provided by the Kenya Ministry of Health Pharmacy and Poisons Board on the 7th of August 2021.

This protocol has been prepared in accordance with Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.

**Trial design**

This phase 1 open label trial of unithiol in healthy Kenyan adults has a primary outcome of determining safety and tolerability of unithiol. Single ascending doses of oral unithiol will be administered with dose escalation decisions dependent on emerging safety data. Two doses of intravenously administered unithiol will also be administered. Following an interim pharmacokinetic analysis and review of safety data from the single dosing stage, the trial will proceed to a multiple ascending dose stage. Participants will be followed-up for a period of 6-months with full reporting of adverse events and serious adverse events. Safety data will be reviewed by the data safety and monitoring board (DSMB) prior to dose escalations.

**Trial objectives**

**Primary objective:** To determine safety and tolerability of unithiol in healthy Kenyan adults.

**Secondary objective:** To define the pharmacokinetic profile of unithiol in healthy Kenyan adults.

**Exploratory objective:** To explore ex vivo efficacy of unithiol at varying doses to inhibit the pathogenic activity of *Echis ocellatus* and other venoms that rely on SVMPs

**Study site**

This single site study will be conducted in Kilifi County, Kenya. Participants will be recruited from Ngerenya, Chasimba and Kilifi townships and will reside within the Kilifi Health and Demographic Surveillance System (KHDSS)⁶. Screening, dosing, and follow-up visits will be conducted at a clinical trial facility at Pwani University, Kilifi.

**Recruitment**

Members of the KHDSS will be approached using established recruitment strategies such as barazas, health talks, mobilization of community health volunteers and fieldworkers. Information giving sessions will be conducted by appropriately trained study personnel. Individuals who are interested in taking part will have ample time to read the patient information sheet. Contact details will be collected if available in accordance with our data collection policies. Those interested in the trial will be given written patient information in the appropriate language and invited to KEMRI-CGMRC or an appropriate facility for further information giving and informed consent.

The aim will be to enrol a diverse population from the KHDSS, including rural areas and the Kilifi township. Eligible consenting subjects will be sequentially screened until the required numbers are met. Ideally, equal numbers of male and female subjects will be enrolled (i.e., there will be a cap for each gender) to maintain a representative sample. Female subjects will be asked to demonstrate they are taking appropriate contraception from the screening visit (or the date of access to contraception for participants agreeing to referral to the health facility for this purpose) until 2 months after receiving the study drug (equivalent to two menstrual cycles).

Subjects will be allocated to a dosing cohort using stratified permuted block randomization. Stratification will be according to sex and age.

**Study population**

Healthy Kenyan adults will be invited to volunteer for this phase I clinical trial. The study team will aim to enrol people representative of a rural Kenyan population, within the constraints of the inclusion/exclusion criteria. There will be no restrictions based on income, education, and no requirement to speak English language. Ideally, there will be equal numbers of male and female subjects within each cohort.

**Inclusion criteria**

- Capable of giving informed consent
- Male or female
- KHDSS resident
- 18–64 years old (inclusive)
- Body weight 50–120kg
- In good health, as determined by the investigator following medical history, drug history, examination, vital signs, electrocardiogram (ECG), and blood tests
- Willing to be admitted to the in-patient facility for up to 5 days for dosing and intensive blood sampling
- On effective contraception as defined by: Use of effective method of contraception for duration of study...
(women only). We will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject’s entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Exclusion criteria

- Prescribed a concomitant medication other than paracetamol or an appropriate contraceptive, which in the opinion of the Investigator warrants exclusion.
- Any significant current or history of cardiovascular, respiratory, renal, or hepatic disease.
- Subjects who have taken any non-prescribed herbal medication or mineral supplement in the preceding 7 days, which in the opinion of the Investigator warrants exclusion.
- Subject with clinically significant abnormal vital signs at screening
- Abnormal laboratory findings deemed significant by the Investigator
- Subjects who are pregnant or lactating
- Decline pre-trial screening, including human immunodeficiency virus (HIV) testing
- HIV positive subjects will be excluded from the trial and, if not already receiving appropriate clinic follow-up, would be referred to a government clinic for ongoing care
- Subjects with asthma (due to possible risk of exacerbation with allergic type skin reactions to unithiol)
- Subjects that have donated blood within the past 3 months
- Subjects who in the opinion of the investigator should not participate

Pre-dose exclusion criteria

Following pre-dose assessments, subjects may be excluded from the dosing cohort for the following reasons. This exclusion may be temporary, and the subject could join a later dosing cohort if the Investigator identifies an abnormality that is likely to resolve within an acceptable period, such as an acute infection.

- Clinically significant vital signs or 12 lead ECG findings
- Clinically significant abnormal laboratory findings
- Intercurrent illness
- Deviation from study restrictions (unless in the opinion of the Investigator these deviations will not interfere with the study procedures, compromise safety, or affect the study results. Any such deviations will be recorded in the source data and documented in the trial master file (TMF).

Screening

Subjects will be consented and then screened during a 3-month period prior to being dosed. Participants that are not dosed within 1-month of being screened will be re-screened. It is anticipated that screening will be held once before the single dosing stage and secondly prior to the multiple dosing stage. Additional screening dates may be needed depending on the time taken to dose escalate. The screening visit will be conducted by a clinician at KEMRI-CGMRC or an appropriate facility. The patient information sheet will be given, and the information will be provided verbally and understanding confirmed prior to seeking written consent.

Following provision of written consent, the following information and procedures will be recorded and performed as part of the screening assessments:

- Demographics including gender, race/ethnic origin, age
- Review of any recent symptoms (including cough, weight loss, fever, night sweats, diarrhoea, dysuria)
- A comprehensive medical history including a systematic inquiry, a family history, and a history of allergies
- Prescribed and non-prescribed medication received in the past 3 months
- Confirmation of contraception use in female subjects of childbearing age*
- Vital signs, including blood pressure, pulse rate, and axillary body temperature
- Physical examination
- Height, weight, and mid upper arm circumference

* Continuous use of an effective method of contraception until 2 months after receiving the final dose of unithiol is required for female participants of childbearing age (unless permanently sterile following hysterectomy). For those with no contraception, they will be referred for contraception at the relevant health facility. For female participants, we will ask them to attend with their family planning records for verification. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include combined oral contraceptives, injectable progestogen, implants of etenogestrel or levonorgestrel,
intrauterine device or intrauterine system, male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository), and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

The following investigations will be undertaken:

- Resting 12 lead ECG
- For female subjects aged 18 to 64 years: Pregnancy test
- Full blood count
- Sodium, potassium, urea, and creatinine
- Alanine aminotransferase (ALT) and bilirubin
- Urine dip (protein, blood, or glucose)
- Random blood glucose
- Viral serology (HBSAg, Hepatitis C virus serology, HIV1 & 2 antigen antibody)
- Malaria film and malaria rapid test

Once all the above information has been collected, the Investigator will decide if it is appropriate for the subject to be enrolled into the study. Data on all consenting screened subjects will be recorded and the reason for participant exclusions will be documented.

The investigational medical product (IMP)
The IMP will be Dimaval® oral capsules and solution for injection sourced from Heyl (the manufacturer).

Product names
International non-proprietary name: unithiol
Commercial Name: Dimaval®

Synonyms: DMPS, sodium (DL)-2,3-dimercaptopropane-1-sulfonate, sodium 2,3–66 dimercaptopropanesulphonate

IUPAC name: Sodium D,L-2,3-dimercapto-1-propanesulfonic acid

CAS No.: 4076-02-2

Chemical formula: H2C(SH)-HC(SH)-H2CSO-3Na.H2O

Relative molecular mass: 228.28 (monohydrate)

Conversions: 1g = 4.4mmol; 1mmol = 228.3mg; 1g/L = 4.4mmol/L; 1mmol/L = 0.228g/L

Formulations
The oral form of Dimaval will consist of 100mg capsules. According to the summary of product characteristics, each capsule contains 108.56 mg (RS)-2,3-bis(sulfanyl)propane-1-sulfonic acid, sodium salt 1 H2O corresponding to 100 mg DMPS sodium salt.

The Dimaval solution for injection consists of 5mL volume ampoules containing 250 mg of DMPS-Na. According to the summary of product characteristics, each ampoule contains 271.4 mg (RS)-2,3-Bis(sulfanyl)propane-1-sulfonic acid, sodium salt 1 H2O (DMPS sodium salt 1 H2O) corresponding to 250 mg (RS)-2,3-Bis(sulfanyl)propane-1-sulfonic acid, sodium salt (DMPS-Na)

Dose
Participants will be dosed in cohorts of 8. Cohorts for single oral doses are abbreviated as ‘C’, single intravenous dose cohorts as ‘CIV’ and multiple oral dosing cohorts as ‘CM.’ There will be four single ascending oral dosing cohorts (C1-C4), two intravenous dosing cohorts (CIV1 and CIV2) and two multiple dosing cohorts (CM1 and CM2). The anticipated dose escalations are summarised in Table 2. The dosing regimen in Table 2

<table>
<thead>
<tr>
<th>Table 2. Summary of dosing regimens.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single dosing (and CIV1)</td>
</tr>
<tr>
<td>Cohort name</td>
</tr>
<tr>
<td>C1</td>
</tr>
<tr>
<td>C2</td>
</tr>
<tr>
<td>C3</td>
</tr>
<tr>
<td>C4</td>
</tr>
<tr>
<td>CIV1</td>
</tr>
<tr>
<td>Multiple dosing (and CIV2)</td>
</tr>
<tr>
<td>CM1</td>
</tr>
<tr>
<td>CM2</td>
</tr>
<tr>
<td>CIV2</td>
</tr>
</tbody>
</table>

Additional dosing cohorts may be added depending on emerging safety data. Eight cohorts and the above dose escalations represent the maximum dose increases that would occur assuming reassuring safety data.
represents the anticipated dose escalations that will be followed should the DSMB have no safety concerns. The highest single oral dose of unithiol that will be administered is 1,500 mg. Any increase above 1,500 mg would require approval from the Sponsor and the ethics and regulatory committees. Following review by the DSMB, dose levels may be repeated, smaller increments in dose escalation may be adopted or dose levels may be lower than the preceding dose level and, therefore, additional cohorts may be included. The DSMB will make these decisions based on adverse event data.

**Justification for the proposed dose, route of administration, dosage regimen and treatment period**

The starting dose for the oral single ascending dose stage will be 300 mg. This is a routine dose recommended for the treatment of heavy metal poisoning.\(^{18,38}\) The maximum dose that will be administered during the oral single ascending dose stage will be 1,500 mg. This dose has been selected based on pre-clinical in-vitro assays that have shown that high concentrations of unithiol are required to inhibit the pro-coagulant effects of snake venom.\(^{31}\) In this experiment, 150 µM of unithiol was required to prevent consumption coagulopathy. Given that previous in-human pharmacokinetic analysis has identified a C\(_{\text{max}}\) of 25 µM following administration of 300 mg oral,\(^{33}\) it has been estimated that a dose of 1,500 mg would be required to achieve a peak plasma concentration sufficient to inhibit coagulopathy. Published reports of dose levels of unithiol equivalent or higher than 1,500 mg oral suggest that this dose is safe.\(^{32,33,35}\)

The dose that will be given to the first intravenous dosing cohort (CIV1) will be 3 mg/kg. This has been selected as it is at the lower range of the routinely recommended dose for acute heavy metal poisoning (3–5 mg/kg).\(^{27,39}\) Previous pharmacokinetic analyses have shown that 3 mg/kg intravenous achieves an initial plasma concentration of 100 µM.\(^{22}\) At least one further intravenous dosing cohort will be included. The dose administered will be decided by the DSMB based on emerging data from the first stage of the trial. This dose is expected to be 5 mg/kg, although a dose of up to 10 mg/kg may be selected, depending on emerging safety and pharmacodynamic data.

For the multiple dosing cohorts (CM1 and CM2), the study team will select doses that show the optimum profile for treating snakebite, based on safety, tolerability and any available pharmacokinetic and pharmacodynamic data. If the pharmacodynamic data shows a dose response relationship and is deemed to demonstrate sufficient reliability, the investigators will aim to select CM1 based on a minimum dose associated with adequate ex vivo inhibition of SVMPs. The CM2 dose will be selected by the investigators based on the highest dose (between 300 and 1,500mg oral) that is safe and tolerated during single dosing. The preliminary pharmacokinetic data from the single dosing stage will be modelled to identify CM1 and CM2 doses and dose intervals, that will not cause accumulation of the study drug. Ideally, a regimen of no more than four times per day dosing would be preferred (unlike in heavy metal poisoning where 1–2 hourly dosing is used), to optimize adherence to the regimen.

**Dose escalation schedule**

In every cohort, subjects will be dosed at least 30 minutes apart. In cohorts C2, C3 and C4, 1 participant will receive a sentinel dose prior to the remaining 7 participants being dosed. Minimum time-periods of observation between dose escalations are summarised in Figure 1a and Figure 1b.

C2 begins with a sentinel dose and the remaining 7 subjects will be dosed at least 24 hours after this. C3 will begin with a sentinel dose and the remaining 7 subjects will be dosed 72 hours after this. Cohort C4 will be dosed a minimum of 1 week after C3 and will also commence with a sentinel dose followed by 3 days until the remaining 7 subjects are dosed. The CIV cohort will be dosed in tandem with C3. Dose escalation decisions will not be dependent on the results of the pharmacodynamic assay, as this analysis is exploratory and has not been validated. Between the single dosing stage and the multiple dosing stage, preliminary pharmacokinetic data will be made available. Multiple dosing will only proceed once the DSMB have reviewed adequate pharmacokinetic data from the single dosing stage to be satisfied that the proposed dosing regimen will not lead to accumulation of the study drug. A minimum of one week after the final dose is given in CM1, dosing of CM2 will commence. The flowchart (Figure 1) summarises the process of dose escalation.

**Sample size determination**

As this is a phase I clinical trial, with a primary aim to evaluate the safety of the escalating unithiol doses, a sample size calculation has not been conducted. Participants will be dosed in groups of eight, which is a commonly used design in phase I clinical trials.\(^{40}\)

The number of cohorts will be guided by the safety and tolerability of unithiol. Additional cohorts may be added if adverse events occur that, following review by the DSMB, warrant smaller increments in dose escalation or expansion at a dose level.

**Randomisation procedure**

Subjects will be allocated to a dosing cohort using stratified permuted block randomization. Stratification will be according to sex and age. Following the screening visit (and prior to attendance at the in-patient facility), participants will be asked to attend to receive the results of the clinical investigations, to be informed of their eligibility and to be informed of their allocation following randomization. Throughout the study, a minimum of four participants (randomly selected) will be on stand-by for each dosing cohort – to replace any participants that cannot be dosed. There is no placebo group and therefore this is not a randomized controlled trial. Participants in dosing cohorts that involve sentinel dosing will undergo a second step of randomization, to allocate individuals for sentinel dosing. The study team member responsible for randomizing subjects
Figure 1a. Single Dosing Escalation Strategy.
will be blinded to the subject’s identity and any information related to the subject except for their sex and age. Once randomization is complete, cohort allocation will be unconcealed. The study team and the participants will not be blinded.

Enrolment into the trial will begin the night before dosing. The participant will be reviewed by a study team member in the in-patient facility. Any concerns or questions the participant may have will be answered. Any participants that do not arrive or cannot be dosed due to becoming ineligible (e.g., due to illness) will be replaced, as detailed below.

**Trial procedures**

*Table 3a* and *Table 3b* summarise the daily study procedures for the single and multiple dosing stages, respectively (additional assessments or blood draws may be added based on emerging data or if clinically indicated). Participants will be admitted to an in-patient facility the night prior to dosing and monitored until 24 hours after their last dose of unithiol and will be reviewed as an out-patient on days 2, 5 and 42 (with telephone follow-up at 6-months).

**Procedures for collection of clinical samples**

*Timing and volume of clinical samples*

*Figure 2a, Figure 2b* and *Figure 2c* summarize the blood and urine sampling protocol for the single and multiple dose stages, respectively. The timing of blood and urine samples may be adjusted, and any such changes will be provided to the approval committees via a written notification. This would be because of emerging safety, pharmacokinetic or pharmacodynamic data.

*Justification of frequency and volume of blood sampling*

Frequent blood sampling is required to understand the pharmacokinetic profile of unithiol. As this drug has a short-half-life, less frequent drug monitoring would lead to inaccurate estimates of the \( C_{\text{max}} \) and \( \text{AUC} \) (area under the curve). For the pharmacodynamic analysis, it is important for us to understand the duration of efficacy. As unithiol is rapidly metabolised and excreted, the duration of venom inhibition may be short. By understanding this duration, better decisions of optimal dose frequency can be obtained. Blood volumes are based on required amounts for each assay, with the need for storage in duplicate being accounted for. Frequency of sampling and blood volumes...
### Table 3a. Study schedule – single dosing regimen.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Screening (Day -28 to Day -2)</th>
<th>Randomisation (Day -27 to Day -2)</th>
<th>Day -1</th>
<th>Day 0</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 5</th>
<th>Day 42</th>
<th>6-month telephone visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-patient stay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data (including smoking history)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral serology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provide results to investigations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study residency:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check out</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-residential visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study drug administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Safety and tolerability:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse event recording&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs (including blood pressure and pulse rate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axillary body temperature</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 lead ECG&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical laboratory evaluations (including haematology, clinical chemistry, and urinalysis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (and height at first visit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood sampling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacodynamics:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity</td>
<td>Screening (Day -28 to Day -2)</td>
<td>Randomisation (Day -27 to -2)</td>
<td>Day -1</td>
<td>Day 0</td>
<td>Day 1</td>
<td>Day 2</td>
<td>Day 3</td>
<td>Day 5</td>
<td>Day 42</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>In-patient stay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic data (including smoking history)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral serology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provide results to investigations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study residency:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check out</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-residential visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study drug administration</strong>&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety and tolerability:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse event recording&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs (including blood pressure and pulse rate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axillary body temperature</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 lead ECG&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical laboratory evaluations (including haematology, clinical chemistry, and urinalysis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (and height at first visit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood sampling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacodynamics:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ECG, electrocardiogram.

<sup>a</sup> Females aged 18 to 64 years. Performed in urine.

<sup>b</sup> In house stay until 24 hours post-dose.

<sup>c</sup> The timings of all measurements to be performed during the study may be subject to change based on the ongoing review of the safety, tolerability, pharmacokinetic and pharmacodynamic results.

<sup>d</sup> Serious adverse events will be recorded from enrolment, and adverse events will be recorded from dose administration until the final follow up Visit.

<sup>e</sup> Resting 12 lead ECG: at Screening; and Day 1 post dose and prior to discharge from inpatient facility. Additional ECG recordings will be taken at the discretion of the responsible clinician.

<sup>f</sup> Doses anticipated to be administered four times per day for up to 72 hours.
may increase if adverse events occur or if the emerging pharmacokinetic or pharmacodynamic data demonstrate unanticipated findings. Nevertheless, the total blood volumes will not exceed 500 mL per 3 months, as per 2001 Kenya Ministry of Health Blood Transfusion Guidelines.

**Interim visits**

Subjects will be admitted to the inpatient facility the day prior to dosing and monitored there by clinical study staff for a minimum of 24 hours following the last dose of unithiol. The rationale for this time window post dosing is based on the short half-life of unithiol, which is 4 hours, as well as the pre-existing safety data.

Subjects will be asked to visit the KEMRI-CGMRC or an appropriate facility on days 2, 5 and 42 for single dosing and days 5 and 42 for multiple dosing. They will be monitored for adverse events and have samples collected at these visits (Table 3 and Figure 2). The final planned review will be via telephone at 6 months (with the option for a face-to-face review, if necessary). If a participant cannot be contacted by telephone, arrangement for a home visit will be made, to ensure that the participant remains safe and well.

**Unscheduled visits**

If the participant is unwell, they will be strongly encouraged to seek treatment with the study team and given emergency contact numbers to facilitate this. Out of hours’ participants will be advised to contact the study clinician and in the event of an emergency, to attend Kilifi County Hospital. Subjects will be required to be resident in KHDSS during the study. Medical emergency plans will be in place with the possibility to admit patients to the Aga Khan Hospital in Mombasa, should intensive care be required. Transport related to unscheduled (and scheduled) visits will be reimbursed.

**End of treatment visit**

The final visit for each cohort will be at 6 months. As per Table 3 and Figure 2, this will include adverse event recording. If adverse events have occurred, the final visit may be later, at the discretion of the study team. If adverse events are ongoing, follow-up will be continued until the event resolves or until the condition has stabilised.

**Follow-up visit(s)**

Each subject will participate in a single treatment period only, and they will be in an in-patient facility starting from the day...
before dosing until 24 hours after last dose. The multi-dosing regimen is for a period of up to 72 hours and participants will therefore be monitored for 72 to 96 hours. Out-patient visits at KEMRI-CGMRC or the in-patient facility will be arranged on day 2, 5 and day 42 post-dose for the single dosing group. The multiple dosing group will be reviewed as an out-patient on day 5 and day 42. All participants will undergo telephone follow-up at 6 months. Depending on emerging data, additional visits (including additional telephone consultations) may be required.

**Study restrictions**

**Dose escalation holding criteria**

If any of the following scenarios occur within a group with reasonable possibility of a causal relationship with unithiol, dose escalation will be stopped pending safety review, prior to higher dose levels being evaluated. In the case a serious adverse event occurring, this will be reported in accordance with section 11.7 of this protocol, including reporting to the Sponsor and the DSMB within 48 hours.

- Clinically relevant signs or symptoms or intolerable adverse events of similar nature occur in 2 or more subjects in a group that in the opinion of the Investigator warrant stopping of dose escalation
- One or more subjects report a serious adverse event considered by the Investigator to be related to the study drug
- Two or more severe adverse events occur which are considered by the Investigator to be related to the study drug
- Dose escalations will only occur after a minimum period of days, depending on the dose received (as specified in Figure 1a and Figure 1b).

**Cohort dosing holding criteria**

If any of the following scenarios occur within a group with reasonable possibility of a causal relationship with unithiol, further dosing within a cohort will be stopped pending review by the Data Safety Monitoring Committee.

---

**Table: Single IV Dosing Cohorts**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Screening</th>
<th>Admission</th>
<th>Follow up</th>
<th>Total Volume of Blood Samples</th>
<th>Total Blood per Participant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D-28</td>
<td>D-1</td>
<td>D0</td>
<td>D0</td>
<td>D0</td>
</tr>
<tr>
<td>Time (hours)</td>
<td>-</td>
<td>-</td>
<td>Pre-dose</td>
<td>End of Infusion</td>
<td>1</td>
</tr>
<tr>
<td>Drug intake</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Veneupuncture (mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full blood count</td>
<td>4</td>
<td>4</td>
<td></td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Biochemistry</td>
<td>5</td>
<td>5</td>
<td></td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B and C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD sample</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>PK sample</td>
<td>8.5</td>
<td>8.5</td>
<td>8.5</td>
<td>8.5</td>
<td>8.5</td>
</tr>
<tr>
<td>Urine PK</td>
<td>x</td>
<td></td>
<td>Continuous collection</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Urine βHCG</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV test (RDT)</td>
<td>Drop</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria RDT</td>
<td>Drop</td>
<td>Drop</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria film</td>
<td>Drop</td>
<td>Drop</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total blood volume per day (mL)</td>
<td>9.3</td>
<td>9.2</td>
<td>99</td>
<td>25.5</td>
<td>25.5</td>
</tr>
<tr>
<td>Day</td>
<td>D-28</td>
<td>D-1</td>
<td>D0</td>
<td>D1</td>
<td>D2</td>
</tr>
<tr>
<td>Blood collections per day</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Figure 2b.** Blood and urine sampling times and volumes during inpatient stay and out-patient follow-up – single intravenous dosing.
Clinically relevant signs or symptoms or intolerable adverse events of similar nature occur in 2 or more subjects in a group that in the opinion of the Investigator warrant stopping of dose escalation.

One or more subjects report a serious adverse event considered by the Investigator to be related to the study drug.*

Two or more severe adverse events occur which are considered by the Investigator to be related to the study drug.

If a serious adverse event were to occur during sentinel dosing, then dosing of other subjects would be held until review by the DSMB.

Should the threshold for a holding rule be met, there would be a study hold then an ad-hoc DSMB meeting would be convened before further dosing. All safety follow-ups would continue as planned.

Concomitant medication
This will be assessed at the time of the first screening visit and the participants will be asked if they have taken any medication within the past 3 months. Medications taken within 3 months of the screening study will not necessarily result in exclusion, rather this will be at the discretion of the principal investigator (PI). The study team will emphasize to participants the importance of the medical team overseeing clinical care during the study period. Participants will be encouraged to contact the study team for all medical attention during the study. If any medication is required, the name, strength, frequency of dosing and reason for use will be documented in the participants source data. Participants will be asked to phone the study team should they require medical review or change in contraception.

Appropriate contraceptive medication is an acceptable concomitant medication and is an inclusion criterion for women of childbearing age (as per section 6.1.2 Screening). Should a participant require a prescription for contraception they would be referred to KCH services or their local health Centre/dispensary.

**Patient obligations**

**Diet**
Standard meals will be provided for all subjects whilst they are resident at the trial unit. Dietary requirements will be confirmed at the screening visit. Dietary intake is unlikely to affect elimination of unithiol as the drug is renally excreted and is not subject to metabolism by liver enzymes.
During periods of intensive pharmacokinetic blood sampling (the day of dosing), meals will be identical for each group. Otherwise, meals will not be restricted.

Alcohol

Subjects will adhere to the following alcohol restrictions:

- Alcohol is not permitted from 36 hours before check-in until discharge from the inpatient facility. Participants will be made aware of this. There will not be active efforts to police this restriction.
- Alcohol is not permitted 36 hours prior to non-residential visits.
- Alcohol intake is unlikely to have a significant effect on the assessment of safety or pharmacodynamic or pharmacodynamic during this trial. There may be a modest (diuresis induced) increase in renal excretion of unithiol following alcohol intake.

Smoking

No restrictions. Standard health and safety procedures (such as not smoking in the health facility) will be in place.

Exercise

No restrictions.

Blood donation

Subjects must not donate blood from enrolment until 3 months after the final follow-up visit.

Contraception

Use of an effective method of contraception for the duration of study (and until 2 months after last receiving the study drug) for female participants aged 18–64 years (unless permanently sterile following hysterectomy). For those not on effective contraception, referral to an appropriate family planning service will be offered. For female participants, we will ask them to attend with their family planning records for verification. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include combined oral contraceptives, injectable progestogen, implants of etenogestrel or levonorgestrel, intrauterine device or intrauterine system, male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository), and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Prior/concomitant therapy

The study team will emphasize to participants the importance of the medical team overseeing clinical care during the study period. Participants will be encouraged to contact the study team for all medical attention during the study. If any medication is required, the name, strength, frequency of dosing and reason for use will be documented in the participants source data. Participants will be asked to phone the study team should they require medical review or change in contraception.

Prohibited medication

Participants will be encouraged to seek medical care from the study team during their follow-up period. Participants will be discouraged from taking over the counter medications and medications from other providers except in urgent situations, where delay to treatment could be harmful. Receipt of a concomitant medication for an acute illness would normally not lead to exclusion from the trial.

Participant withdrawals

Subject withdrawal criteria

Subjects will be withdrawn for multiple reasons including some of those listed below:

- Any clinically relevant signs, symptoms, or adverse events that in the opinion of the Investigator warrant subject withdrawal
- Non-compliance with the study restrictions, as considered applicable by the Investigator
- Loss to follow up (applies to a subject who consistently does not return for protocol study visits, is not reachable by telephone or any other means of communication and/ is not able to be located).
- At the discretion of the Investigator, if inter-current illnesses occur that may invalidate the study data, if the subject was enrolled in violation of the study protocol, or if a significant protocol violation occurs (note, asymptomatic malaria infection is not anticipated to require exclusion from the study, although subjects will be monitored closely)
- Subject decision
- On the advice of DSMB

Managing withdrawals

- If a subject is withdrawn, the reason will be recorded in the case report form (CRF). If withdrawal is the result of a serious adverse event (AE), the investigator will offer to arrange for appropriate specialist management of the problem and the ethical committee, DSMB and regulatory authority will be informed in a timely manner. The extent of follow up will be determined by a medically qualified investigator but will be at least for the whole study period. Subjects withdrawn prematurely for any reason will not receive further doses of unithiol, although they will be encouraged to come back to the clinic for safety evaluation. Additionally, participants will not receive the IMP if they do not meet the eligibility criteria.
- If a participant withdraws from the study, blood samples collected before his/her withdrawal from the trial will be used/stored unless the participant specifically requests otherwise. In all cases of subject withdrawal, apart from those of complete consent withdrawal, long-term safety data collection for participants, including some procedures such as safety blood investigations, will continue so far as the participant is willing to consent. Where
participants withdraw consent for follow up, this will be respected and follow up will be discontinued.

- If a volunteer withdraws/is withdrawn from the study after receiving unithiol, they will be encouraged to continue to complete the recommended period of safety monitoring. If the subject requests to leave after taking unithiol but before being discharged from the inpatient facility, they will be offered telephone follow-up.

Replacing withdrawn participants
For each dosing protocol (single dosing and multiple dosing), a minimum of four participants (randomly selected) will be on stand-by – to replace any subject withdrawals or non-attendances. The stand-by subjects will have undergone screening and written consent and will be asked to be available during the day before and the day of dosing and will be reimbursed for lost wages accordingly. Subjects that complete dosing and monitoring at the inpatient facility, but who do not attend out-patient follow-up (Day 2, 5 and 42) will not be replaced.

Storage, packaging, dispensing, and administration of the investigational medicinal product
Storage
The capsules and solution for injection will be stored in a pharmacy with temperature regulation as this should not exceed 25 °C. The capsules will be kept dry as per recommendations on summary of product characteristics. The shelf-life for the commercially available pharmaceutical preparation Dimaval® is 3 years for the capsules and the ampoules. The expiry date is stated on each package.

Packaging and labelling
Packaging and labelling of the investigational medical product will comply with the Kenya Pharmacy and Poisons Board (PPB) labelling requirements, as per their guidelines for the conduct of clinical trials in Kenya.

Dispensing procedures
The study drug will be stored in the pharmacy at KCH according to the manufacturer’s specifications. The drug, dose and subject identity will be confirmed by one pharmacist or pharmacy technician and one study team member.

Dose administration
Oral unithiol will be administered with 240mL of water and will be swallowed as whole tablet(s). Food will not be consumed for at least one-hour after dosing, as per product literature.

Intravenous dosing will be infused over a minimum period of 5 minutes, as per a previous study, with the subject lying flat with blood pressure monitoring during the infusion, at 5 minutes and at 15 minutes (more frequent monitoring will be provided if the responsible clinician identifies a clinical need). The solution for infusion will be prepared according to the product literature.

Treatment compliance
All doses of the IMP will be administered under direct observation by a trained study team member. Participants can withdraw from the study if they no longer wish to receive the medication.

Overdose
Overdose of unithiol will be prevented as subjects will not have access to the medication, except for the individual doses they are to receive. The IMP will be stored securely in a locked drug cabinet. Doses will be confirmed by two study team members before administration.

In the rare event of overdose, participants will be managed with necessary supportive measures (including intravenous fluids) and the PI, in discussion with clinical investigators, hospital staff and the DSMB will decide whether transfer to a facility with intensive care and dialysis/haemofiltration facilities is necessary.

Rescue medication
There is no antidote to unithiol. Dialysis does remove the drug.

Assessment of pharmacokinetics and pharmacodynamics
Pharmacokinetics
The secondary outcome is to define the pharmacokinetic profile of unithiol. Although most of the pharmacokinetic analysis will be completed after all the subjects have completed follow-up in the trial, preliminary pharmacokinetic data will be made available prior to commencing the multiple dosing stage of the trial. The purpose of this preliminary data will be to predict a dose and dosing interval that will provide consistent plasma drug levels and not pose a risk of accumulation of the study drug following multiple dosing. Multiple dosing will only proceed once the DSMB have reviewed adequate pharmacokinetic data from the single dosing stage to be satisfied that the proposed dosing regimen will not lead to accumulation of the study drug.

This will be undertaken in collaboration with the University of Liverpool. Samples will be shipped to the Liverpool Bioanalytical Facility (GCP Laboratories, William Henry Duncan Building, 6 West Derby Street, University of Liverpool, L7 8TX) for the purposes of measuring drug concentrations. This is necessary to fulfil regulatory requirements for pharmacokinetic analysis. Drug concentrations will be quantified by validated liquid chromatography-mass spectrometry.

Pharmacodynamics
An exploratory outcome is to assess the efficacy of unithiol to inhibit the pathogenic actions of venom, *ex vivo*. If the pharmacodynamic assay produces results that are deemed reliable, then pharmacodynamic data from the single dosing stage could be used to guide the dosing regimen for the multiple dosing stage. If the pharmacodynamic assay does not produce useful results, then dose and dosing frequency decisions will be made based on safety and preliminary pharmacokinetic data.
Ex vivo assays will be developed for the purposes of establishing a dose-response and estimating a pharmacodynamic profile. These assays will rely on spiking subjects’ plasma with venom ex vivo and measuring activity of snake venom metalloproteinases. These assays are being developed for the purposes of this study, and a published validated assay does not exist. It would not be appropriate to assign these assays as primary outcome variables as they are experimental and represent an indirect estimate of efficacy.

These assays will continue to be refined during this study. They primarily represent a tool to compare venom metalloproteinase inhibition between subjects receiving different doses of unithiol, rather than a direct measure of efficacy. Where possible, these assays will be conducted and refined in the laboratory facilities at KEMRI-CGMRC. Split samples will also be shipped to Liverpool School of Tropical Medicine Centre for Snakebite Research & Interventions (LSTM CSRI).

### Study governance: local safety monitor and data safety monitoring board

#### Local safety monitor
- The local safety monitor (LSM) will be a clinician resident in Kilifi (therefore likely to be linked to or a staff member of KWTRP) but independent of the study team. The LSM will act as a semi-independent assessor of participants experiencing important safety events at the request of the DSMB and will provide their observations to the DSMB and/or local clinicians or study team members where appropriate.

#### Data and safety monitoring board
- The DSMB will include a minimum of 3 members with at least 1 clinician with expertise of the local context and 1 statistician.
- The DSMB charter has been uploaded the Harvard Dataverse.
- At least one of the following investigators will attend DSMB meetings: Dr Abouyannis, Dr Hamaluba or Professor Laloo (either remotely or in-person). The DSMB will have access to all relevant data on administration of unithiol. The independent local clinician will have expert knowledge of the Kenyan context. The DSMB will be convened at the start of the study before unithiol is administered, to review the protocol and their responsibilities. Planned DSMB meeting will occur before every dose escalation, although the DSMB can hold additional ad-hoc meetings if they deem it necessary. A local safety monitor (LSM) will also be appointed prior to this to provide independent safety assessments of participants. The DSMB will review:
  - all SAEs/SUSARs (serious adverse events/suspected unexpected serious adverse reactions)
  - SAEs will be reviewed alongside an updated summary of all severe adverse events reported to that date.
  - Clinically relevant signs or symptoms or intolerable adverse events of similar nature occurring in 2 or more subjects in a group
  - Summaries of all adverse events will be reported to the sponsor and DSMB. However, investigators or the local safety monitor can request the DSMB to review any non-serious non-severe adverse events that raise concern. The Investigators will be responsible for reporting a summary of safety data to the Scientific and Ethics Review Unit (SERU) and PBB, as per their guidelines.

### Assessment of safety

#### Adverse events (AEs)

Both solicited and unsolicited AEs will be recorded on the participant’s CRF until the end of the 6-month follow-up period. The diagnosis, date and time of onset, outcome, severity, and relationship to unithiol administration will be established. Details of any treatment or concomitant interventions will be recorded.

If any pregnancies occur with 2 months of receiving unithiol, the participant will be referred for appropriate antenatal care. Unithiol has a short half-life and, as participants will undergo pregnancy testing, it is very unlikely that any pregnancies will occur whilst unithiol is detectable in the circulation. Nevertheless, if this were to occur during the trial the participant would be followed-up until term and (as a minimum) their baby would be examined by a paediatrician at 6-weeks following birth. Any congenital anomaly or birth defect would be reported as a serious adverse event.

During the in-patient admission, the study clinician will evaluate for solicited adverse events. Solicited AEs will also be elicited at every follow-up visit (day 2, day 5, day 42 and 6 months). Assessing the severity of adverse events will be the responsibility of a clinical or medical officer.

#### Solicited adverse events

Solicited adverse events are those that have been associated with unithiol and are listed in the summary of product characteristics. These are summarised in Table 4.

#### Definitions and monitoring of AEs

The definitions of adverse events (AE), adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR), and suspected unexpected serious adverse reactions (SUSAR) are available in Table 5.

### Assessing the relationship between an adverse event and the investigational medicinal product

The causal relationship between an adverse event and the study drug is defined in Table 6.

### Severity grading of adverse events

All adverse events will be severity graded using the definition shown in Table 7. Severity grading of abnormal vital signs will be categorised as shown in Table 8.

### Follow-up of adverse events

Adverse events likely to be related to the study drug, whether serious or not, which persist at the end of the trial will be followed up by the investigator until their resolution or
### Table 4. Solicited adverse events.

<table>
<thead>
<tr>
<th>Category</th>
<th>Solicited adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Nausea, weakness, loss of appetite, dysgeusia (change in taste), painful injection site, abdominal pain</td>
</tr>
<tr>
<td>Physical observations</td>
<td>Shivering, fever, skin reactions (itching rash), Stevens-Johnson's syndrome, hypotension (with intravenous unithiol)</td>
</tr>
<tr>
<td>Laboratory abnormalities</td>
<td>Leucopaenia, transaminitis, kidney injury (raised urea and creatinine)</td>
</tr>
</tbody>
</table>

### Table 5. Definitions of adverse events.

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse Event (AE)</strong></td>
<td>Any untoward medical occurrence in a patient or clinical investigation subject occurring in any phase of the clinical study whether or not considered related to the study drug. This includes an exacerbation of pre-existing conditions or events, intercurrent illnesses, or drug interactions. Anticipated day-to-day fluctuations of pre-existing conditions, that do not represent a clinically significant exacerbation, will not be considered AEs. Discrete episodes of chronic conditions occurring during a study period will be reported as adverse events to assess changes in frequency or severity. Unsolicited adverse events will be documented in terms of a medical diagnosis(es). When this is not possible, the AE will be documented in terms of signs and symptoms observed by the investigator or reported by the subject. Pre-existing conditions or signs and/or symptoms (including any which are not recognized at study entry but are recognized during the study period) present in a subject prior to the start of the study will be recorded on the Medical History form within the subject's case report form (CRF).</td>
</tr>
<tr>
<td><strong>Adverse Reaction (AR)</strong></td>
<td>An untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant. The phrase &quot;response to an investigational medicinal product&quot; means that a causal relationship between a trial medication and an AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out. All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the trial medication qualify as adverse reactions. It is important to note that this is entirely separate to the known side effects listed in the SmPC. It is specifically a temporal relationship between taking the drug, the half-life, and the time of the event or any valid alternative aetiology that would explain the event.</td>
</tr>
<tr>
<td>Serious Adverse Event (SAE)</td>
<td>A serious adverse event is any untoward medical occurrence that: • results in death • is life-threatening • requires inpatient hospitalisation or prolongation of existing hospitalisation • results in persistent or significant disability/incapacity • consists of a congenital anomaly or birth defect Other ‘important medical events’ may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences. NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. “Hospitalisation” signifies that the subject has been detained (usually involving an overnight stay) at a hospital for observation and/or treatment above that routinely offered at the inpatient trial facility. When in doubt as to whether hospitalisation occurred or was necessary, the adverse event will be considered as serious. Hospitalisation for elective surgery or routine clinical procedures, which are not the result of an adverse event, will not be considered adverse events and should be recorded on a clinical assessment form and added to the CRF.</td>
</tr>
<tr>
<td>Serious Adverse Reaction (SAR)</td>
<td>An adverse event that is both serious and, in the opinion of the reporting Investigator, believed with reasonable probability to be due to one of the trial treatments, based on the information provided.</td>
</tr>
<tr>
<td>Suspected Unexpected Serious Adverse Reaction (SUSAR)</td>
<td>An adverse reaction, the nature or severity of which is not anticipated based on the applicable product information is considered as an unexpected adverse drug reaction. Where the adverse reaction is also considered to have a possible, probable, or definite relationship with the drugs given, and also meets the criteria for a serious adverse reaction, it is termed a Suspected Unexpected Serious Adverse Reaction (SUSAR). These events are subject to expedited reporting as for SAEs.</td>
</tr>
</tbody>
</table>

To avoid confusion or misunderstanding of the difference between the terms ‘serious’ and ‘severe,’ the following note of clarification is provided: ‘severe’ is often used to describe intensity of a specific event, which may be of relatively minor medical significance. ‘Seriousness’ is the regulatory definition supplied above.

Table 6. Categorizing a causal relationship.

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No Relationship: No temporal relationship to study product; Alternate aetiology (clinical state, environmental or other interventions); Does not follow known pattern of response to study product</td>
</tr>
<tr>
<td>1</td>
<td>Unlikely: Unlikely temporal relationship to study product; Alternate aetiology likely (clinical state, environmental or other interventions); Does not follow known typical or plausible pattern of response to study product</td>
</tr>
<tr>
<td>2</td>
<td>Possible: Reasonable temporal relationship to study product; Event not readily produced by clinical state, environmental or other interventions; Similar pattern of response to this form of therapeutic intervention</td>
</tr>
<tr>
<td>3</td>
<td>Probable: Reasonable temporal relationship to study product; Event not readily produced by clinical state, environment, or other interventions; Known pattern of response seen with study product</td>
</tr>
<tr>
<td>4</td>
<td>Definite: Reasonable temporal relationship to study product; Event not readily produced by clinical state, environment, or other interventions; Known pattern of response seen with study product</td>
</tr>
</tbody>
</table>

Table 7. Severity grading of adverse events.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>Mild: Transient or mild discomfort (&lt; 48 hours); no medical intervention/therapy required</td>
</tr>
<tr>
<td>2</td>
<td>Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required</td>
</tr>
<tr>
<td>3</td>
<td>Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible</td>
</tr>
</tbody>
</table>

Table 8. Severity grading of abnormal vital signs.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Grade 1 (mild)</th>
<th>Grade 2 (moderate)</th>
<th>Grade 3 (severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>37.6°C - 38.0°C</td>
<td>38.1°C - 39.0°C</td>
<td>&gt;39.0°C</td>
</tr>
<tr>
<td>Tachycardia (bpm)*</td>
<td>101 – 115</td>
<td>116 – 130</td>
<td>&gt;130</td>
</tr>
<tr>
<td>Bradycardia (bpm)**</td>
<td>50 – 54</td>
<td>40 – 49</td>
<td>&lt;40</td>
</tr>
<tr>
<td>Systolic hypertension (mmHg)***</td>
<td>141 – 159</td>
<td>160 – 179</td>
<td>≥180</td>
</tr>
<tr>
<td>Diastolic hypertension (mmHg)***</td>
<td>91 – 99</td>
<td>100 – 109</td>
<td>≥110</td>
</tr>
<tr>
<td>Systolic hypotension (mmHg)***</td>
<td>85 – 89</td>
<td>80 – 84</td>
<td>&lt;80</td>
</tr>
</tbody>
</table>

*Taken after ≥10 minutes at rest
**When resting heart rate is between 60 – 100 beats per minute. Use clinical judgement when characterising bradycardia among some healthy subject populations, for example, conditioned athletes.
***Use clinical judgement, particularly in subjects with low body weight. Consider checking lying and standing blood pressure to test for a postural drop of >20 mmHg if safe to do so. Do not record as an adverse event if hypotension is asymptomatic (e.g., absence of light-headed feeling).
stabilisation, or until causality is determined to be unrelated to trial interventions. All AEs will be managed as per Kenyan national clinical guidelines.

Moreover, any serious adverse event likely to be related to unithiol and occurring after trial termination should be reported by the investigator according to the procedure described below.

Outcome of any non-serious adverse event occurring within 6 months of the last dose of unithiol (i.e., unsolicited adverse event) or any SAE reported during the entire study will be assessed as:

- Recovered/resolved
- Not recovered/not resolved
- Recovering/resolving
- Recovered with sequelae/resolved with sequelae
- Fatal (SAEs only)

Subjects who have moderate or severe on-going adverse events that are not unithiol linked will be referred to an appropriate government hospital/health facility on completion of the study and will be advised to consult a physician if the event is not considered to be related to the study drug. If it is related to the study drug, a follow-up visit will be arranged to manage the problem and to determine the severity and duration of the event. If appropriate, specialist review using government services will be arranged.

Documenting AEs
Solicited and unsolicited AEs will be recorded on the participant’s CRF. The diagnosis, date and time of onset, outcome, severity, and relationship to dosing will be established. Details of any treatment or concomitant interventions will be recorded.

These will be recorded from the time of written informed consent until 6 months post cessation of trial treatment.

The following information will be collected:

- Full details in medical terms and case description
- Event duration (start and end dates, if applicable)
- Action taken
- Outcome
- Seriousness criteria
- Causality (i.e., relatedness to trial drug / investigation), in the opinion of the investigator
- Whether the event would be considered expected or unexpected.

Reporting serious adverse events (SAEs) and/or unexpected AEs
- Every SAE occurring throughout the trial must be reported by telephone, e-mail, or fax to the sponsor (LSTM) and the DSMB within 48 hours, even if the investigator considers the SAE not related to the study drug. The investigator will then complete a hard copy SAE report as soon as possible and submit this to the sponsor, DSMB, SERU and PPB in accordance with their respective guidelines.
- Any relevant information concerning the adverse event that becomes available after the SAE report form has been sent (outcome, precise description of medical history, results of the investigation, copy of hospitalisation report, etc.) will be forwarded to the sponsor, DSMB, SERU and PPB in a timely manner, the anonymity of the subjects shall be respected when forwarding this information.
- The DSMB may ask for the study to be stopped, or for an extended study hold to be applied while further data and information are sought. The DSMB will make its recommendation to the Sponsor, who will have ultimate responsibility for acting on the recommendation.
- Any study related SUSAR or serious adverse event related to participation in the study must be reported by telephone, e-mail, or fax to the sponsor (LSTM) and the DSMB within 48 hours. A hard copy SUSAR report will be completed as soon as possible and submitted to the sponsor, DSMB, SERU and PPB in accordance with their respective guidelines.
- The SUSAR and SAE reports will be submitted to PPB through the online system at www.pv.pharmacyboardkenya.org. The sponsor pledges to inform the authorities of any trial discontinuation and specify the reason for discontinuation.

Emergency procedures
Equipment and drugs
The inpatient facility will be stocked with the appropriate equipment and drugs to manage emergencies that may arise whilst testing an IMP. This will include giving sets, intravenous fluids, oxygen, ventilation equipment and adrenaline.

Follow-up of participants
Every reasonable effort will be made to follow-up subjects who have adverse events. Any subject who has an ongoing adverse event at the follow-up visit will be followed up, if possible, until resolution.

Notification of deaths
All deaths will be reported to the sponsor, SERU, and PPB, irrespective of whether the death is related to disease progression, the IMP, or an unrelated event.

Pregnancy
All pregnancies within the study period (either the subject or the subject’s partner) will be reported to the Principal Investigator and Sponsor within 24 hours of notification. The pregnancy will be followed to term at minimum, and the baby will be examined at 6 weeks after delivery (with further reviews to be arranged at the discretion of the responsible paediatrician).

Procedures for reporting any protocol violation(s)
If any changes to the study are necessary during the study a formal amendment will be presented to the sponsor prior to
submission to the relevant ethical and regulatory agencies for approval unless to eliminate an immediate hazard(s) to study participant without prior ethics approval. Any unforeseen and unavoidable deviations from the protocol will be documented and filed as a protocol non-compliance in the Trial Master File, with explanation.

Statistics
The statistical analysis plan has been uploaded to the Harvard Dataverse[41]. The study is not powered to detect statistically significant differences between groups, although a cut-off p-value ≤0.05 will be applied to any comparisons.

Pharmacokinetics
Pharmacokinetic outputs will include drug concentrations at each dose level during the first 24-hours and at each follow-up visit. Except for preliminary data to guide multiple dosing regimens that avoid accumulation, pharmacokinetic analysis will be completed after all participants have been dosed. Pharmacokinetic analysis will be undertaken at the University of Liverpool, UK. Area under the curve will be calculated from the plasma drug concentration time curve during the initial 24-hours. The maximal concentration (Cmax), time to maximum concentration (Tmax) and the half-life (t1/2) will be calculated.

Pharmacodynamics
Pharmacodynamic outputs will vary between assay and are exploratory. For the fluorogenic substrate assay the area under the fluorescence-time curve will be compared between dosing groups using ANOVA and an appropriate post-hoc test (e.g., Tukey’s). The time to plateau and time to mid-point of fluorescence (Km) of the fluorescence-time curves will also be compared with this approach. These same measures will be calculated for the plasma clotting assay. Further assays will be developed, and analysis will be planned as appropriate.

Demographics and baseline characteristics
Demographic data will include age, gender, and race. Baseline data will include medical history, drug history, height, weight, full blood count, renal function, liver function and electrocardiogram. These will be presented using tables and descriptive statistics. Continuous variables will be described using means, standard deviations, medians, and interquartile ranges, as appropriate. Categorical data will be presented as counts and percentages. Missing data will be presented.

Safety analyses
Adverse event frequency, severity grade (mild, moderate, or severe), and relationship to IMP (no relationship, unlikely, possible, probable, and definite) will be described and reported to the DSMB before any dose escalations. These will be presented by organ system involved and clinically appropriate terminology will be used. Changes to alanine aminotransferase (ALT), plasma creatinine, haemoglobin, white cell count and platelet count will be presented to the DSMB at every safety review. Grading of laboratory values will use the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events version 2.1 July 2017[2]. These scales are not based on a coastal Kenyan population. We have modified these for several of our SERU approved trials (R21 (SERU 3711), S4V01 (SERU 3796, CHMI-SIKA (SERU 3190)) to ensure grading reflects normative values in our population.

Amendments to the statistical analysis plan
Minor amendments to the statistical analysis will be made by the investigator/ supervisor/statistician. Any changes that significantly affect the protocol or reporting of adverse events will require approval from the sponsor and research ethics committees and regulatory authority.

Data management
The data management plan has been uploaded to the Harvard Dataverse (https://doi.org/10.7910/DVN/LJOYSO). The PI will have overall responsibility for managing the data. A designee to the PI will be responsible for receiving, entering, cleaning, querying, analysing, and storing all data from the study. Responsibility for this may be delegated to the study data management team.

Data capture methods
Data will be entered into the participant’s paper CRF and subsequently transferred to an electronic database for analysis. A clinical quality management plan (CQMP) will be developed prior to the trial commencing. This will outline the processes for evaluating appropriate use of consent forms, CRFs and any study specific procedures (SSPs).

A laboratory analytical plan (LAP) will be developed prior to the study commencing. Lab samples will be tracked, and clinical results will be reported using the electronic system.

Archiving
The investigator must keep the consent forms and trial master file for at least 10 years after the completion or discontinuation of the trial. The anonymized electronic databases will be maintained beyond this period.

Missing data
Missing data will be recorded as such using appropriate coding that is compatible with statistical software. Missing data that impacts on the validity of the results will be clearly reported in scientific publications of this work. Records will be kept detailing the reason for any missing data and occurrence of missing data will be kept to a minimum.

Patient data protection/confidentiality
All study data for analysis will be de-identified. Participants will be identified via their unique study number. Paper records containing study data will be stored in a locked filing cabinet in a lockable study office. Electronic data will be stored on laptops approved by KEMRI-CGMRC IT department and will be password protected with encrypted hard-drives. Data will be backed up on the KEMRI-CGMRC cloud storage system, which is secured with password protection and approved for use for clinical research data. Participant information will only be shared with those directly involved in conducting this trial.
The master list of participant identifiable information will not be removed from the KEMRI-CGMRC site where it will be stored in a locked cabinet in a lockable office.

Archiving and record retention
Hard copies of documents will be kept for a period of 10 years following completion of the trial. Data and clinical samples will be kept for 15 years at KWTRP. Samples sent to the UK will be kept for a maximum of 10 years and then either destroyed or returned to KWTRP.

Data sharing
- Data will be shared with LSTM Centre for Snakebite Research & Interventions (CSRI) and the University of Liverpool, and this will be stated on the consent form and patient information leaflet.
- Liverpool School of Tropical Medicine is the Sponsor
- Prior to transfer of data, participants’ names and other identifiable information will be removed.
- Data will only be accessed by individuals with a direct role in conducting this research.
- Access by others would require appropriate approvals including from SERU.
- Data published in peer-reviewed journal and presented at scientific meetings will be available open access. Participants will not be identifiable from the data presented.

Study monitoring
Regular monitoring will be performed according to International Council for Harmonisation (ICH) Good Clinical Practice (GCP) and a Monitoring Plan. Monitors will check whether the clinical trial is conducted, and data are generated, documented, and reported in compliance with the protocol, GCP and the applicable regulatory requirements. The site team led by the PI will be responsible for local submissions to the regulators and all the staff will have good clinical practice training prior to study start. The PI will give direct access to study documents for monitoring and auditing.

Quality control and quality assurance
The study team at the trial site will conduct regular quality checks to ensure that the trial is being conducted, data is being recorded, analysed, and accurately reported according to the protocol, trial standard operating procedures (SOPs) and the clinical quality management plan, and in compliance with ICH GCP. Audits will be conducted in the laboratories according to an agreed audit schedule.

Ethics
Approval will be sought from the CGMRC Centre Scientific Committee (CSC, Kilifi KEMRI Scientific & Ethics Review Unit (SERU), LSTM research and ethic committee (REC) and the Pharmacy and Poisons Board. Written informed consent will be obtained from each participant.

Human Subjects
As this trial will involve human subjects, the following guidelines will be observed:

“First, do no harm.”

The Investigators are aware that this phase I trial exposes risk to healthy participants. Unithiol is a medication which has been used in humans for several decades and has reassuring safety data. Higher doses than have previously been administered will be used. The animal data suggests low toxicity at higher dose levels, as does the limited data from small observational reports in humans. Additional precautions will be undertaken during administration of higher dose levels, including sentinel dosing. Close monitoring will be in place for the 24-hours after dosing, and after this time plasma levels of unithiol are anticipated to be negligible. As data exist describing the adverse event profile of unithiol in humans, participants will be made aware of the solicited adverse events and early presentation to the study will be encouraged and supported if they occur. Trial insurance through the Sponsor will be in place and will cover the costs of treating any adverse events at appropriate government health facilities. As well as the risks that have been described above and in section 4 (safety data), there will be certain inconveniences. Subjects will be expected to reside at the in-patient facility during dosing and will be asked to attend follow-up appointments. Remuneration will be provided in accordance with KEMRI reimbursement guidelines. Volunteers will be made aware, during consenting, of their responsibilities and the inconveniences involved in becoming a study participant.

Direct benefit to study subjects or the community
There are limited direct benefits to those involved. The screening process may identify health conditions that would otherwise have gone unnoticed (such as high blood pressure or diabetes), and thus allow for earlier treatment. There may be some perceived benefits although this will just be close clinical monitoring during the trial.

There may be benefit to the local community if this compound were found to be effective in treating snakebite, although it should be noted that the research so far has suggested the strongest benefit would be seen for victims of a snake that reside in West Africa. West Africa is home to a type of snake (Echis ocellatus or saw-scaled viper) that causes many bites that result in uncontrolled bleeding. The experiments of unithiol in mice showed that the drug worked best against the venom of this snake. Further experiments of this drug for snakes that exist in Kenya are being undertaken. The target of this drug (SVMPs) is predominant in most viper species, and it is feasible that this drug may have efficacy for species relevant to Kenya, such as the puff adder.

Conducting the trial in Kilifi will provide a platform for further trials of new treatments for snakebite to be tested.
Community considerations
KEMRI-Wellcome has a dedicated team which coordinates all engagements with the programme. A CAST (Communication Advice for Studies) group will be formed and will develop a community engagement plan. The cast group will be composed of community liaison group (CLG) and study team members.

Kilifi North and South sub-County Hospital Management Teams (SCHMT) and Pwani University will be approached and informed of the study protocol.

Members of the Kilifi County living in Ngerenya, Chasimba and Kilifi township will be approached through community engagement activities. KWTRP personnel will raise awareness of the trial with permission of community leaders. There will be sensitization through the health management teams and village elders. Following this barazas will be held. At community meetings, focused pertinent information will be provided including the purpose, risks, duration, monetary compensation, exclusion criteria and inclusion criteria of the trial. Interested individuals will have ample time to read the PIS prior to consent. Those interested in the trial will be given written patient information in the appropriate language.

Informed consent
Potential participants will be provided with verbal and written information during community meetings. They will be encouraged to ask questions about the study. Potential participants that attend the screening visit will be given further information about the clinical trial, including the risks and their responsibilities. Potential participants will be given time to consider their decision and the opportunity to ask any questions. They will be aware that enrolment is voluntary and that they can withdraw. Participants that choose to withdraw at screening will be compensated for out-of-pocket expenses and their transport reimbursed according to the actual cost based on public transport. Consent forms will be available in English, Giriama and Swahili. Consent will be provided in writing and participants will maintain the right to withdraw at any time. Participants will be made aware that once they have taken the IMP that they would be advised to remain under close observation for their own safety. For participants that withdraw from the study after taking the IMP, all reasonable efforts will be made to maintain their safety, including telephone follow-up.

Compensation
As participants will be resident for at least 24-hours and have at least three further visits as out-patients, out of pocket expenses and travel costs will be incurred. These financial costs will be remunerated by the trial, according to KEMRI reimbursement guidelines. For each day engaged in the study, the participant will receive 500 KES (£3.50) (except for days where they will be accommodated for an overnight stay at the inpatient facility). Reserve participants that are not asked to attend for dosing will be reimbursed 500 KES (£3.50), as it is expected that they have made themselves available for the day of dosing. Per day and night spent as a resident, the participant will receive 2000 KES (£14). These costs adhere to KEMRI guidelines and will be updated if they change in the period before trial is conducted. Costs of travel will vary depending on distance travelled and will be provided based on actual cost of using public transport.

Safety
All monitoring, clinical examination and sample collection will be undertaken by appropriately trained nursing and clinical staff. Subjects will be dosed and monitored in a clinical environment within an inpatient facility. A physician will be available throughout the study period. Costs of managing acute illness caused by the study drug will be met by the study and appropriate insurance will be in place for participants. Participants will be followed up for a minimum of 6 months. If there are ongoing features of adverse events at 6 months, follow-up will be extended where appropriate.

Reporting dissemination and notification of results
Results will be published in an open-access journal. Individual results with clinical relevance will be provided to participants in real-time. Summaries of the outcomes of the trial will be provided during community meetings in the areas from which participants are recruited. It is not anticipated that substantial information in this form will be available until at least the second year of the trial, and this will be made clear during initial meetings. Where possible, participants will receive feedback on the progress of the trial during their follow-up visits, including at the planned telephone consultation 6 months after dosing.

Study status
The study has started. Participant screening is ongoing.

Conclusions
Snakebite envenoming is an important cause of morbidity and mortality, contributing to more deaths per year than any other neglected tropical disease. There is an urgent need to identify new therapeutics for snakebite envenoming. Current antivenoms are prohibitively expensive, complex to manufacture, can only be administered intravenously, have a high risk of acute allergic reactions, and are restricted by high species specificity. Unithiol has the potential to overcome each of these limitations. SVMPs are an important component of many snake venoms, including: Echis, Bitis, Daboia, Bothrops, and Crotalus. Unithiol and other small molecule venom inhibitors therefore have the potential to inhibit a globally diverse range of snake venoms.

Before unithiol can be assessed in a phase II efficacy trial, further information is needed on an appropriate oral dose. Unithiol was developed as a treatment for heavy metal poisoning, for which treatment often consists of a short course of in-patient intravenous therapy, followed by a prolonged course of low dose oral therapy. The safety and tolerability of oral doses above 300 mg has not been confirmed, although reports from the use of high intravenous doses suggest it may be safe. For the treatment of snakebite, administration of therapeutic oral doses
is important, as many patients with snakebite will make initial contact with a healthcare facility at the local clinic level. There can often be a long delay before patients reach a secondary or tertiary care facility that stocks antivenom, and a potential advantage of unithiol is that it can be stocked and administered at the local clinic level.

This phase I clinical trial will assess the safety and tolerability of escalating oral doses of unithiol. A multiple dose regimen of oral unithiol, that offers consistent and safe plasma concentrations, will be defined. To better understand the pharmacokinetics of unithiol, two dosing groups will receive intravenous unithiol. It is anticipated that this trial will provide important information for developing a dosing regimen that can be progressed to a phase II clinical trial in patients with snakebite. This will be the first phase I clinical trial of an oral therapeutic for snakebite envenoming and represents an important step forward in improving therapeutic options for people with this neglected and dangerous disease.

Sponsor
The Liverpool School of Tropical Medicine in the Sponsor for this study. For further information, please contact the LSTM research governance department:

lstmgov@lstmed.ac.uk
+44(0)151 705 3100

Liverpool School of Tropical Medicine
Pembroke Place Liverpool
L3 5QA UK

Data availability
Underlying data
No underlying data are associated with this article.

Extended data
Harvard Dataverse KWTRP Research Data Repository: TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming Phase 1 (Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Kenyan Adults). https://doi.org/10.7910/DVN/LIOYSO*

This package contains the following extended data:
- Data Management Plan TRUE1_15102021.pdf
- DSMB charter TRUE1_14042021.pdf
- Statistical analysis plan TRUE1_31032021.pdf
- TRUE-1 PIL ICF v3_01012021.pdf

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

References
